Sponsored Links
| Avila Therapeutics Presents Data Demonstrating The Relevance Of Its Btk Inhibitor, AVL-292, In B Cell Malignancies Such As CLL |
 |
 |
 |
| Medical News - Hematology | |||
|
Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the presentation of data on AVL-292, a clinical-stage inhibitor of Bruton's tyrosine kinase (Btk), at the 16th Congress of the European Hematology Association (EHA)... Read more: Blood / Hematology News From Medical News Today
|